Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jukyung Kang"'
Autor:
Alexander Benet, Troy Halseth, Jukyung Kang, April Kim, Rose Ackermann, Santhanakrishnan Srinivasan, Steven Schwendeman, Anna Schwendeman
Publikováno v:
Pharmaceutics, Vol 13, Iss 8, p 1263 (2021)
Exenatide, a glucagon-like peptide-1 receptor agonist, is the active pharmaceutical ingredient in Byetta® and Bydureon®, two type 2 diabetes drug products that have generics and multiple follow-up formulations currently in development. Even though
Externí odkaz:
https://doaj.org/article/cfdddcbf97ef416498e9b3f921369de4
Autor:
Jill L. Kinzer, Troy A. Halseth, Jukyung Kang, Sang Yeop Kim, Preethi Kumaran, Michael Ford, Sergei Saveliev, St John Skilton, Anna Schwendeman
Publikováno v:
International Journal of Pharmaceutics. 635:122646
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0b2c2ef6ea3c535ef87bdeadcd6b729
https://doi.org/10.1016/j.ijpharm.2023.122646
https://doi.org/10.1016/j.ijpharm.2023.122646
Autor:
Steven P. Schwendeman, Bin Qin, Justin K Y Hong, Yan Wang, Alexander Benet, Jennifer Walker, Avital Beig, Jukyung Kang, Aishwarya Chandrashekar, Anna Schwendeman, Tinghui Li, Rose Ackermann
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 158:401-409
Bydureon® (Bdn) is a once-weekly injectable long-acting release (LAR) product for adults with type 2 diabetes based on PLGA microspheres encapsulating the glucagon like peptide (GLP-1) analog, exenatide. Despite its widespread use in type 2 diabetes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85086dc3f3c3d1b9afa32012171c69cb
https://doi.org/10.1016/j.ejpb.2020.10.008
https://doi.org/10.1016/j.ejpb.2020.10.008
Autor:
Jill Coghlan, Jukyung Kang, John C. Fjeldsted, Daniel A. Polasky, Anna A. Schwendeman, Daniel D. Vallejo, Brandon T. Ruotolo, Ruwan T. Kurulugama, Carolina Rojas Ramírez
Publikováno v:
Analytical chemistry. 93(48)
Ion mobility-mass spectrometry (IM-MS) and collision-induced unfolding (CIU) assays of monoclonal antibody (mAb)-based biotherapeutics have proven sensitive to disulfide bridge structures, glycosylation patterns, and small molecule conjugation levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2da71fc5899695404a5193c57ef0b0f
https://pubmed.ncbi.nlm.nih.gov/34808055
https://pubmed.ncbi.nlm.nih.gov/34808055
Publikováno v:
Arthritis Rheumatol
Systemic lupus erythematosus (SLE) patients exhibit accelerated development of atherosclerosis and increased incidents of cardiovascular disease (CVD) that cannot be explained by traditional risk factors alone. Accumulating evidence suggests that red
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::110a7b45e2b179830f1c781002c7898b
https://doi.org/10.1002/art.41059
https://doi.org/10.1002/art.41059
Autor:
Lei Shen, Yaoxin Li, Kelsey Ernst, Jukyung Kang, Zhan Chen, Hiren Patel, Bei Ding, Jie Tang, Lindsey Drake, Wenmin Yuan, Anna Schwendeman
Publikováno v:
International Journal of Nanomedicine. 14:3069-3086
Background: Synthetic HDLs (sHDLs), small nanodiscs of apolipoprotein mimetic peptides surrounding lipid bilayers, were developed clinically for atheroma regression in cardiovascular patients. Formation of HDL involves interaction of apolipoprotein A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c5c9ae773473c7212f457f9e406c9cf
https://doi.org/10.2147/ijn.s179837
https://doi.org/10.2147/ijn.s179837
Autor:
Steven P. Schwendeman, Jukyung Kang, Solomon Z. Okbazghi, Yuwei Tian, Anna Schwendeman, Michael J. Ford, Eric Carlson, K. Ilker Sen, Thomas J. Tolbert, Karthik Pisupati, Alexander Benet, Brandon T. Ruotolo, Sergei Saveliev
Publikováno v:
mAbs. 9:1197-1209
Remsima™ (infliximab) is the first biosimilar monoclonal antibody (mAb) approved by the European Medical Agency and the US Food and Drug Administration. Remsima™ is highly similar to its reference product, Remicade®, with identical formulation c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3168c25bc5d17c44f3ed1e497bae1299
https://doi.org/10.1080/19420862.2017.1347741
https://doi.org/10.1080/19420862.2017.1347741
Autor:
Anna Schwendeman, Jukyung Kang, Zeynab Izadi Najafabadi, Troy Halseth, K. Ilker Sen, Michael J. Ford, Daniel D. Vallejo, Brandon T. Ruotolo
Publikováno v:
Analytical and bioanalytical chemistry. 412(3)
Biosimilars are highly similar to, but not identical with, their originator products. As a result, structural differences between originators and biosimilars can be difficult to detect and characterize without the appropriate analytical tools. Theref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0ed3ba1b8f6373335d4c96673acb88
https://pubmed.ncbi.nlm.nih.gov/31853605
https://pubmed.ncbi.nlm.nih.gov/31853605
Autor:
Tyler S. Hageman, Jill Coghlan, Derek R. White, K. Ilker Sen, Anna Schwendeman, Jukyung Kang, Steven P. Schwendeman, Sergei Saveliev, Alexander Benet, Michael J. Ford, Thomas J. Tolbert, Brandon T. Ruotolo, Sang Yeop Kim, David D. Weis, Daniel D. Vallejo
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 146
Biosimilars are poised to reduce prices and increase patient access to expensive, but highly effective biologic products. However, questions still remain about the degree of similarity and scarcity of information on biosimilar products from outside o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5789c0cb739018af019c6aa816cf0f7b
https://pubmed.ncbi.nlm.nih.gov/31841688
https://pubmed.ncbi.nlm.nih.gov/31841688
Autor:
Jukyung Kang, Alexander Benet, Steven P. Schwendeman, Karthik Pisupati, Brandon T. Ruotolo, Anna Schwendeman
Publikováno v:
Trends in biotechnology. 36(10)
Structural and functional differences between REMICADE and its two FDA-approved biosimilars appear to have clinical implications. We suggest a personalized biosimilar substitution approach based on prescribed indication, biosimilar afucosylation leve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be2945b41d41182e2be2fd94ec88c8b2
https://pubmed.ncbi.nlm.nih.gov/29861288
https://pubmed.ncbi.nlm.nih.gov/29861288